From single-dose vaccine delivery systems to nanovaccines

Journal of Drug Delivery Science and Technology

Volumn 20, Issue 4, 2010, Pages 267-276

  Vicente, S ^a   Prego, C ^a   Csaba, N ^a   Alonso, M J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Adjuvants; Antigen delivery; Microparticles; Nanocarriers; Nanoparticles; Nanovaccines; Single dose vaccination; Vaccine delivery

Indexed keywords

ANTIGEN; ASOX; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NANOCARRIER; NANOPARTICLE; TETANUS TOXOID; UNCLASSIFIED DRUG;

DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; NANOTECHNOLOGY; NEEDLE FREE VACCINE DELIVERY; NONHUMAN; PARTICLE SIZE; REVIEW; SINGLE DRUG DOSE; TETANUS; VACCINATION;

EID: 78149362896     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(10)50044-3     Document Type: Review

References (113)

1. Plotkin S.A. - Vaccines. - W.B. Saunders Co., Philadelphia, 1994.
2. O'hagan D.T., Rappuoli R. - The safety of vaccines. - Drug Discov. Today, 19, 846-854, 2004.
3. Plotkin S.A. - Vaccines: past, present and future. - Nat. Med., 11 (4) (Suppl.), S5-11, 2005.
4. Liu M.A. - DNA vaccines: a review. - J. Intern. Med., 253, 402-410, 2003.
5. Bambini S., Rappuoli R. - The use of genomics in microbial vaccine development. - Drug Discov. Today, 14 (5-6), 252-260, 2009.
6. Friede M., Aguado M.T. - Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. - Adv. Drug Del. Rev., 57, 325, 2005.
7. Cohen J. - Global health: the new world of global health. - Science, 311, 162-167, 2006.
8. www.gcgh.org (Grand Challenges in Global Health).
9. Galazka A., Milstien J.B., Zaffran M. - Thermostability of Vaccines. - WHO, Geneva, 1998.
10. Matthias D.K., Robertson J., Garrison M.M., Newland S., Nelson C. - Freezing temperatures in the vaccine cold chain: a systematic literature review. - Vaccine, 25, 3980-3986, 2007. (Pubitemid 46616996)
11. Zapata M.I., Peck G.E., Hem S.L., White J.L., Feldkamp J.R. - Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. - J. Pharm. Sci., 73, 3-9, 1984.
12. Haworth E.A., Booy R., Stirzaker L., Wilkes S., Battersby A. - Is the cold chain for vaccines maintained in general practice? - Brit. Med. J., 307 (6898), 242-244, 1993.
13. Samant Y., Lanjewar H., Block L., Parker D., Stein B. - Relationship between vaccine vial monitors and cold chain infrastructure in a rural district of India. - Rural Remote Hlth, 7, 617-631, 2007.
14. Kissmann J., Ausar S.F., Rudolf A., Braun C., Cape S.P., Sievers R.E., Federspiel M.J., Joshi S.B., Middaugh C.R. - Stabilization of measles virus for vaccine formulation. - Hum. Vaccines, 4 (5), 350-359, 2008.
15. Braun L.J., Jezek J., Peterson S., Tyagi A., Perkins S., Sylverster D., Guy D., Lal M., Priddy S., Plzak H., Kristensen D., Chen D. - Characterization of a thermostable hepatitis B vaccine formulation. - Vaccine, 27 (34), 4609-4614, 2009.
16. Abdul-Fattah A.M., Truong-Le V., Yee L., Pan E., Ao Y., Kalonia D.S., Pikal M.J. - Drying-induced variations in physicochemical properties of amorphous pharmaceuticals and their impact on stability. II. Stability of a vaccine. - Pharm. Res., 24 (4), 715-727, 2007.
17. Lang R., Winter G., Vogt L., Zurcher A., Dorigo B., Schimmele B. - Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation. - Drug Dev. Ind. Pharm., 35 (1), 83-97, 2009.
18. Aguado M.T. - Future approaches for vaccine development, Single-dose vaccines using controlled-release delivery systems. - Vaccine, 11 (5), 596-597, 1993.
19. Edwards K.M., Decker M.D. - Combination vaccines consisting of acellular pertussis vaccines. - Pediatr. Infect. Dis. J., 16 (4), S97-S102, 1997.
20. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. - Unsafe injections in the developing world and transmission of blood-borne pathogens: a review. - B World Health Organ., 77 (10), 789-800, 1999.
21. Drain P.K., Nelson C.M., Lloyd J.S. - Single-dose versus multidose vials for immunization programmes in developing countries. - B World Health Organ., 81 (10), 726-731, 2003.
22. Clements C.J., Larsen G., Jodar L. - Technologies that make administration of vaccines safer. - Vaccine, 22, 2054-2058, 2004. (Pubitemid 38581079)
23. Jodar L., Duclos P., Milstien J., Griffiths E., Aguado M.T., Clements C.J. - Ensuring vaccine safety in immunization programmes, a WHO perspective. - Vaccine, 19, 1594-1605, 2001. (Pubitemid 32175718)
24. Clements C.J., Griffiths E. - The global impact of vaccines containing aluminium adjuvants. - Vaccine, 20, S24-S33, 2002. (Pubitemid 34607672)
25. Lindbald E.B. - Aluminium adjuvants - in retrospect and prospect. - Vaccine, 22, 3658-3668, 2004.
26. Brewer J.M. - (How) do alumiun adjuvants work? - Immunol. Lett., 102, 10-15, 2006.
27. Schultze V., D'agosto V., Wack A., Novicki D., Zorn J., Hennig R. - Safety of MF59 adjuvant. - Vaccine, 26 (26), 3209-3222, 2008.
28. Garçon N., Chomez P., Van Mechelen M. - GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. - Expert Rev. Vaccines, 6 (5), 723-739, 2007.
29. Chu D.W., Hwang S.J., Lim F.S., Oh H.M., Thongcharoen P., Yang P.C., Bock H.L., Dramè M., Gillard P., Hutagalung Y., Tang H., Teoh Y.L., Ballou R.W. - Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. - Vaccine, 27, 7428-7435, 2009.
30. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasinham B. - Vaccine adjuvants: current challenges and future approaches. - J. Pharm. Sci., 98 (4), 1278-1316, 2009.
31. Perrie Y., Mohamed A.R., Kirby D., Mcneill S.E., Bramwell V.W. - Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. - Int. J. Pharm., 364, 272-280, 2008.
32. Schijns V.E. - Immunological concepts of vaccine adjuvant activity. - Curr. Opin. Immunol., 12, 456-463, 2000.
33. Burgdorf S., Kautz A., Böhnert V., Knolle P.A., Kurts K. - Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. - Science, 306, 612-616, 2007. (Pubitemid 46683149)
34. Banchereau J., Steinman R.M. - Dendritic cells and the control of immunity. - Nature, 392 (6673), 245-252, 1998.
35. Storni T., Kündig T.M., Senti G., Johansen P. - Immunity in response to particulate antigen-delivery systems. - Adv. Drug Del. Rev., 57, 333-355, 2005.
36. Mondino A., Jenkins M.K. - Surface proteins involved in T cell costimulation. - J. Leukocyte Biol., 55, 805-815, 1994.
37. Chabalgoity J.A., Baz A., Rial A., Grille S. - The relevance of cytokines for development of protective immunity and rational design of vaccines. - Cytokine Growth F R, 18, 195-207, 2007. (Pubitemid 46420552)
38. Zheng J., Si L.S., Song J.M., Sun X.L., Yu J., Wang Y.L. - Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2. - Antivir. Res., 59 (1), 61-65, 2003.
39. Gherardi M.M., Ramírez J.C., Esteban M. - Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. - Histol. Histopatol., 16 (2), 655-667, 2001.
40. www.clinicaltrials.gov.
41. Kumar H., Kawai T., Akira S. - Toll-like receptors and innate immunity. - Biochem. Biophys. Res. Com., 388, 621-625, 2009.
42. Van Duin D., Mezhitov R., Shaw A. - Triggering TLR signaling in vaccination. - Trends Immunol, 27 (1), 49-55, 2006.
43. Manicassamy S., Pulendran B. - Modulation of adaptive immunity with Toll-like receptors. - Semin. Immunol., 21, 185-193, 2009.
44. Didierlaurent A.M., Morel M., Lockman L., Giannini S.L., Bisteau S.L., Carlsen H., Kielland A., Vosters O., Vanderheyde N., Schiavetti F., Larocque D., Van Mechelen M., Garçon N. - AS04, an aluminium salt- and TLR4 agonist-based adjuvant system, induces a transcient localized innate immune response leading to enhanced adaptive immune response. - J. Immunol., 183, 6186-6197, 2009.
45. Pulendran B., Ahmed R. - Translating innate immunity into immunological memory: Implications for vaccine development. - Cell, 124, 849-863, 2006.
46. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., Plebanski M. - Pathogen recognition and development of particulate vaccines: does size matter? - Methods, 40, 1-9, 2006.
47. Tobio M., Schwendeman S.P., Guo Y., Mciver J., Langer R., Alonso M.J. - Improved immunogenicity of acore-coated tetanus toxoid delivery system. - Vaccine, 18, 618-622, 1999. (Pubitemid 29509845)
48. Tobio M., Gref R., Sánchez A., Langer R., Alonso M.J. - Stealth PLA-PEG nanoparticles as nasal protein delivery systems. - Pharm. Res., 15 (270), 275, 1998.
49. Elemanchili P., Lutsiak C.M., Hamdy S., Diwan M., Samuel J. - "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. - J. Immunother., 30 (4), 378-395, 2007.
50. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartamann G., Coester C. - Delivery of cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. - Pharm. Res., 25 (3), 551-562, 2008.
51. Birrenbach G., Speiser P.P. - Polymerized micelles and their use as adjuvants in immunology. - J. Pharm. Sci., 65 (12), 1763-1766, 1976.
52. Preis I., Langer R. - A single-step immunization by sustained antigen release. - J. Immunol. Methods, 28, 193-197, 1979.
53. Blanco M.D., Alonso M.J. - Development and characterization of poly(lactide-co-glycolide) nanospheres. - Eur. J. Pharm. Biopharm., 43 (3), 287-294, 1997.
54. Csaba N., García-Fuentes M., Alonso M.J. - Nanoparticles for nasal vaccination. - Adv. Drug Del. Rev., 61 (2), 140-157, 2009.
55. De La Fuente M., Csaba N., Garcia-Fuentes M., Alonso M.J. - Nanoparticles as protein and gene carriers to mucosal surfaces. - Nanomed., 3 (6), 845-857, 2008.
56. Köping-Högard M., Sánchez A., Alonso M.J. - Nanoparticles as carriers for nasal vaccine delivery. - Expert Rev. Vaccines, 4 (2), 185-196, 2005.
57. Singh M., Chakrapani A., O'hagan D.T. - Nanoparticles and microparticles as vaccine-delivery systems. - Expert Rev. Vaccines, 6 (5), 797-808, 2007.
58. Audran M., Men Y., Johansen P., Gander B., Corradin G. - Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents. - Pharm. Res., 15 (7), 1111-1116, 1998.
59. Hilbert A.K., Fritzsche U., Kissel T. - Biodegradable microspheres containing influenza A vaccine: immune response in mice. - Vaccine, 17 (9-10), 1065-1073, 1999.
60. Tobio M., Nolley J., Guo Y., McIver J., Alonso M.J. - A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. - Pharm. Res., 16, 682-688, 1999.
61. Jaganathan K.S., Singh P., Prabakaran D., Mishra V., Vyas S.P. - Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. - J. Pharm. Pharmacol., 56 (10), 1243-1250, 2004.
62. Feng L., Qi X.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., Nagai T. - Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. - J. Control. Rel., 112, 35-42, 2006.
63. Davis S.S. - The use of soluble polymers and polymer microparticles to provide improved vaccine reponses after parenteral and mucosal delivery. - Vaccine, 24 (S2), 7-10, 2006.
64. Alonso M.J., Gupta R.K., Min C., Siber G.R., Langer R. - Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. - Vaccine, 12 (4), 299-306, 1994.
65. Sánchez A., Gupta R.K., Alonso M.J., Siber G.R., Langer R. - Pulsed controlled-release system for potential use in vaccine delivery. - J. Pharm. Sci., 85 (6), 547-552, 1996.
66. Yoshida M., Babensee J.E. - Molecular aspects of microparticle phagocytosis by dendritic cells. - J. Biomater. Sci. Polymer, 17 (8), 893-907, 2006.
67. Waeckerle-Men Y., Scandella E., Uetz-Von Allmen E., Ludewig B., Gillessen S., Merkle H.P., Gander B., Groettrup M. - Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. - J. Immunol. Methods, 287 (1-2), 109-124, 2004.
68. Alonso M.J., Cohen S., Park T.G., Gupta R.K., Siber G.R., Langer R. - Determinants of release rate or tetanus vaccine from polyester microspheres. - Pharm. Res., 10 (7), 945-953, 1993.
69. Jung T., Koneberg R., Hungerer K.D., Kissel T. - Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice. - Int. J. Pharm., 234 (1-2), 75-90, 2002.
70. Johansen P., Men Y., Audran R.C., G., Merkle H.P., Gander B. - Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. - Pharm. Res., 15 (7), 1103-1110, 1998.
71. Schwendeman S.P., Tobio M., Joworowicz M., Alonso M.J., Langer R. - New strategies for microencapsulation of tetanus vaccine. - J. Microencapsul., 15 (3), 299-318, 1998.
72. Chang A.C., Gupta R.K. - Stabilization of tetanus toxoid in poly(DL-lacti-co-glycolic acid) microspheres for the controlled release of antigen. - J. Pharm. Sci., 85 (2), 129-132, 1996.
73. Schwendeman S.P., Constantino S.H., Gupta R.K., Tobio M., Chang A.C., Alonso M.J., Siber G.R., Langer R. - Strategies for stabilizing tetanus toxoid towards the development of single-dose tetanus vaccine. - Dev. Biol. Stand., 87, 293-306, 1996.
74. Schwendeman S.P., Constantino H.R., Gupta R.K., Siber G.R., Klibanov A.M., Langer R. - Stabilization of tetanus and diphteria toxoids against moisture-induced aggregation. - Proc. Natl. Acad. Sci. USA, 92 (24), 11234-11238, 1995.
75. Sánchez A., Villamayor B., Guo Y., Mciver J., Alonso M.J. - Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. - Int. J. Pharm., 185 (2), 255-266, 1999.
76. Gupta R.K., Alroy J., Alonso M.J., Langer R., Siber G.R. - Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and Guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly-lactide-co-glycolide polymer. - Vaccine, 15 (16), 1716-1723, 1997.
77. Katare Y.K., Panda A.K., Lalwani K., Haque I.U., Ali M.M. - Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine. - Drug Del., 10 (4), 231-238, 2003.
78. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. - Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. - Int. J. Pharm., 245 (1-2), 109-121, 2002.
79. Raghuvanshi R.S., Singh O., Panda A.K. - Formulation and characterization of immunoreactive tetanus toxoid biodegradable polymer particles. - Drug Del., 8 (2), 99-106, 2001.
80. Prego C., Paolicelli P., Díaz B., Vicente S., Sánchez A., González-Fernández A., Alonso M.J. - Chitosan-based nanoparticles for improving immunization against hepatitis B infection. - Vaccine, 28 (14), 2607-2614, 2010.
81. Guidice E.L., Campbell J.D. - Needle-free vaccine delivery. - Adv. Drug Del. Rev., 58, 68-89, 2006.
82. Neutra M.R., Kozlowski P.A. - Mucosal vaccines: the promise and the challenge. - Nat. Rev. Immunol., 6, 148-158, 2006.
83. Holmgren J., Czerkinsky C. - Mucosal immunity and vaccines. - Nat. Med., 11 (4), S45-S53, 2005.
84. Almeida A.J., Alpar H.O., Brown M.R.W. - Immune response to nasal delivery of antigenically intact tetanus toxoid associate with poly(L-lactic acid) microspheres in rats, rabbits and guinea pigs. - J. Pharm. Pharmacol., 45 (3), 198-203, 1993.
85. Somavarapu S., Bramwell V.W., Alpar H.O. - Oral plasmid DNA delivery systems for genetic immunization. - J. Drug Target., 11 (8-10), 547-553, 2004.
86. Eyles J.E., Bramwell V.W., Williamson E.D., Alpar H.O. - Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. - Vaccine, 19, 4732-4742, 2001.
87. Vila A., Gill H., Mccallion O., Alonso M.J. - Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. - J. Control. Rel., 98, 231-244, 2004.
88. Vila A., Sánchez A., Evora C., Soriano I., Mccallion O., Alonso M.J. - PLA-PEG particles as nasal protein carriers: the effect of particle size. - Int. J. Pharm., 292, 43-52, 2005.
89. Vila A., Sánchez A., Tobio M., Calvo P., Alonso M.J. - Design of biodegradable particles for protein delivery. - J. Control. Rel., 78 (1-3), 15-24, 2002.
90. Jani P., McCarthy D.E., Florence A.T. - Nanosphere and microsphere uptake via Peyer patches - observation of the rate of uptake in rat after a single oral dose. - Int. J. Pharm., 86, 239-246, 1992.
91. Jani P., Halwert G.W., Landgridge J., Florence A.T. - Nanoparticle uptake by the rat gastrointestinal mucosa - quantitation and particle size dependence. - J. Pharm. Pharmacol., 42, 821-826, 1990.
92. O'Hagan D.T. - The intestinal uptake and the implications for drug and antigen delivery. - J. Anat., 189, 447-482, 1996.
93. Brayden D.J. - Oral vaccination in man using antigens in particles: current status. - Eur J. Pharm. Sci., 14, 183-189, 2001.
94. Jung T., Kamm W., Breitenbach A., Hungerer K.D., Hundt E., Kissel T. - Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. - Pharm. Res., 18 (3), 352-360, 2001.
95. Gupta P.N., Khatri K., Goyal A.K., Mishra N., Vyas S.P. - M-cell targeted biodegradable PLGA nanoparticles for oral immunization agains hepatitis B. - J. Drug Target, 15 (10), 701-713, 2007.
96. Borges O., Tavares J., De Sousa A., Borchard G., Junginger H.E., Cordeiro-Da-Silva A. - Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. - Eur. J. Pharm. Sci., 32 (4-5), 278-290, 2007.
97. Borges O., Cordeiro-Da-Silva A., Romeijn S.G., Amidi M., De Sousa A., Borchard G., Junginger H.E. - Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. - J. Control. Rel., 114, 348-358, 2006.
98. Davis S.S. - Nasal vaccines. - Adv. Drug Del. Rev., 51, 21-42, 2001.
99. Tobio M., Sánchez A., Vila A., Soriano I.I., Evora C., Vila-Jato J.L., Alonso M.J. - The role of PEG on the stability on digestive fluids and in in vivo fate of PLA-PEG nanoparticles following oral administration. - Colloid Surf., B Biointerfaces, 18 (315), 323, 2000.
100. Csaba N., Caamaño P., Sánchez A., Domínguez F., Alonso M.J. - PLGA-Poloxamer and PLGA:Poloxamine blend nanoparticles: new carriers for gene delivery. - Biomacromolecules, 6 (271), 278, 2005.
101. Santader-Ortega M., Csaba N., González L., Ortega-Vinuesa J.L., Bastos-González D., Alonso M.J. - Protein-loaded PLGA:PEO blend nanoparticles: encapsulation, release and degradation charateristics. - Coll. Polymer Sci., 288 (2), 141-150, 2010.
102. Paolicelli P., Prego C., Sánchez A., Alonso M.J. - Surface modified PLGA-based nanoparticles which can efficiently associate and deliver virus-like-particles. - Nanomed, accepted, 2010.
103. Csaba N., Sánchez A., Alonso M.J. - PLGA:poloxamer and PLGA:poloxamine blend nanostructrues as carriers for nasal gene delivery. - J. Control. Rel., 113 (2), 164-172, 2006.
104. Vila A., Sánchez A., Pérez C., Alonso M.J. - PLA-PEG nanospheres: new carriers for transmucosal delivery of proteins and Plasmid DNA. - Polym. Adv. Technol., 13, 851-858, 2002.
105. Lai S.K., O'hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. - Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. - Proc. Natl. Acad. Sci. USA, 104 (1482), 1487, 2007.
106. Vila A., Evora C., Soriano I., Vila-Jato J.L., Alonso M.J. - PEG-PLA nanoparticles as carriers for nasal vaccine delivery. - J. Aerosol Med., 17, 174-185, 2004.
107. nd Pharm. Sci. Fair, Nice, France, 8-12 June, 2009.
108. Vila A., Sánchez A., Janes K., Behrens I., Kissel T., Vila-Jato J.L., Alonso M.J. - Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. - Eur. J. Pharm. Biopharm., 57, 123-131, 2004.
109. Csaba N., Köping-Högard M., Alonso M.J. - Ionically cross-linked chitosan/tripolyphosphate nanoparticles for oligonucleotide and Plasmid DNA delivery. - Int. J. Pharm., 382 (1-2), 205-214, 2009.
110. Csaba N., Köping-Högard M., Fernández-Megia E., Novoa-Carballal R., Riguera R., Alonso M.J. - Ionically cross-linked chitosan nanoparticles as gene delivery systems: effect of PEGylation degree on in vitro and in vivo gene transfer. - J. Biomed. Nanotech., 5, 162-171, 2009.
111. rd World Conference on Drug Absorption, Transport and Delivery, Clinical Significance and Delivery, EUFEPS, 2005, p. 94.
112. Amidi M., Romeijn S.G., Verhoef J.C., Junginger H.E., Bungener L., Hunckriede A., Crommelin D.J., Jiskoot W. - N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in mouse model. - Vaccine, 25 (1), 144-153, 2007.
113. Peek L.J., Middaugh C.R., Berkland C. - Nanotechnology in vaccine delivery. - Adv. Drug Del. Rev., 60, 915-928, 2008.